Tri-Moxi intraocular injection recalled over glass-like particulate matter
Imprimis NJOF is recalling 314 boxes containing 6,280 pre-filled syringes of Tri-Moxi triamcinolone and moxifloxacin intraocular injection over glass-like particles.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Scored 3 under the risk-of-harm criterion: glass-like particles in an intraocular injection are a stated contaminant, and no injuries are reported.
Plain-English summary
Tri-Moxi (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, from Imprimis NJOF, LLC of Ledgewood, New Jersey, under NDC 71384-746-06, is being recalled.
The reason given in the enforcement record is the presence of particulate matter, described as glass-like particles.
The recall covers 314 boxes of 6,280 pre-filled syringes from lots 25JAN033A and 25JAN033B, expiring 02/12/2026. Distribution was nationwide in the US. The FDA has classified the action as Class II.
Glass-like particles in a product injected into the eye are a stated physical contaminant. Facilities should quarantine affected lots and follow the firm's instructions.
The recalled product
- Product
- Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
- Manufacturer
- Imprimis NJOF, LLC
- Category
- Drug — Intraocular injection
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot: 25JAN033A
- 25JAN033B
- Expires: 02/12/2026.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Imprimis NJOF, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Imprimis NJOF, LLC
See all →- HighDexamethasone and moxifloxacin injection recalled over glass-like particulate matter
FDA (Drugs) · 2026-01-14
- HighIntraocular injection syringes recalled over glass-like particulate matter
FDA (Drugs) · 2026-01-14
- ModerateCyclosporine eye drops recalled as subpotent across many compounded lots
FDA (Drugs) · 2025-11-26
- HighCompounded epinephrine lidocaine vials returned subpotent assay results in stability testing
FDA (Drugs) · 2025-07-30
- ModerateCompounded quadruple ophthalmic solution returned subpotent assay results in stability testing
FDA (Drugs) · 2025-07-30
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereAminocaproic Acid Injection Recalled for Particulate Matter Contamination
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Acetylcysteine Solution Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26